Characterizing the Role of NOTCH2 in Neuroendocrine Tumors
表征 NOTCH2 在神经内分泌肿瘤中的作用
基本信息
- 批准号:10760205
- 负责人:
- 金额:$ 4.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAlabamaAmino AcidsAutomobile DrivingBedsBiologyCRISPR/Cas technologyCancerousCell NucleusCell ProliferationCellsChromogranin AClinicalComplexDataDependenceDevelopmentDiagnosisDiarrheaDiseaseDisease ProgressionDisease remissionEpitheliumExanthemaExcisionFlushingFoundationsFutureGene TargetingGenesGenomicsGoalsGrowthHeart failureHistone Deacetylase InhibitorHormone secretionHormonesHumanIn VitroIncidenceIslet Cell TumorKnock-outLigand BindingMaintenanceMalignant neoplasm of pancreasMalignant neoplasm of urinary bladderMeasurementMentorsMesenchymalMetastatic Neoplasm to the LiverModelingMusNOTCH3 geneNeoplasm MetastasisNeoplasmsNeuroendocrine TumorsNon-Small-Cell Lung CarcinomaNotch Signaling PathwayNude MiceOncogenicOncologyOperative Surgical ProceduresOrganOutcomeOutcome MeasurePalliative CarePancreatic Ductal CarcinomaPathway AnalysisPathway interactionsPatient-Focused OutcomesPatientsPatternPhenotypePhysiciansPlayPrimary NeoplasmPrimary carcinoma of the liver cellsProductionProgression-Free SurvivalsProliferatingProteinsRecurrenceResearchRoleSamplingScanningScientistSeminalSerumSignal PathwaySignal TransductionSmall Interfering RNASymptomsSystemic TherapyTestingTimeTissue MicroarrayTrainingTransfectionTumor BiologyTumor Cell LineUniversitiesWidespread DiseaseWorkXenograft Modelcareercell growthcell motilityclinically relevantcurative treatmentsdisabling symptomeffective therapyexperiencegastrointestinalgene networkimprovedin vivoinsightknock-downlung CarcinomamedulloblastomamicroCTmigrationmortalitymouse modelneoplastic cellnotch proteinnovelnovel therapeuticsoverexpressionpatient prognosispublic health relevancereduce symptomsresponseside effecttargeted treatmenttreatment strategytumortumor growthtumor progressiontumor xenografttumorigenesis
项目摘要
PROJECT SUMMARY
Pancreatic neuroendocrine tumors (pNETs) are the second most common malignancy of the pancreas, with an
overall survival of 3.6 years and successful surgery the only treatment offering potential for cure. However,
around 40-95% of pNETs are metastatic at the time of initial diagnosis, with local recurrence within the
resection bed as the norm. Furthermore, patients with liver metastases from pNETs often have debilitating
symptoms such as uncontrollable diarrhea, flushing, skin rashes, and heart failure. There are few systemic
therapies that have proven to be clinically useful, and those that have still bear widely variable response rates
and have poor side effect profiles. The goal of this proposal is to determine the role of Notch2 in the
proliferation, metastasis, and hormone-secreting phenotype of NETs, and evaluate Notch2 as a
predictor of patient outcomes. Preliminary data from our lab suggests that overexpression of Notch2 results
in an increase of the proliferative rate of NET cells, while decreasing their hormone secretion. Our data also
suggest that Notch2 is upregulated in metastatic pNETs compared to primary tumors. Seminal data from one
of the largest genomic studies to date on pNETs has also identified Notch2 as a key master-regulator of pNET
metastasis, representing a key convergence of dependencies required for disease progression and the
establishment of metastasis. Therefore, it is my hypothesis that Notch2 functions in an oncogenic role in
NETs and drives tumor progression, resulting in a more aggressive phenotype and portending worse
patient prognosis. To evaluate this hypothesis, we will conduct phenotypic characterization (proliferation,
hormone production, migration) on Notch2-overexpressing pNET cell lines that have been transiently and
stably transfected. We will similarly evaluate pNET cell lines with Notch2 knockdown via siRNA, as well as
stable knockout pNET cell lines generated using CRISPR-Cas9. We will then conduct similar studies in vivo
using a liver metastasis mouse model whereby Notch2-overexpressing and Notch2 pNET cell lines are injected
into athymic mice. Using this model, we will evaluate tumor growth and metastasis via microCT, in addition to
hormone secretion over a 16-week period. We will then conduct endpoint analysis of tumors and mouse
organs. Lastly, we will immunohistochemically analyze the expression of Notch2 using pNET tissue
microarrays derived from human patients that have undergone surgical resection at the University of Alabama
at Birmingham and evaluate the relationships between the expression of Notch2, Notch2 pathway
components, and various patient outcome measures. This study will yield valuable information on the effects of
Notch2 in pNETs that can help to guide future targeted therapeutic efforts and inform an understanding of
pNET biology.
项目概要
胰腺神经内分泌肿瘤(pNET)是胰腺第二常见的恶性肿瘤,
总生存期为 3.6 年,成功的手术是唯一有可能治愈的治疗方法。然而,
大约 40-95% 的 pNET 在初次诊断时已发生转移,且局部复发
切除床为常态。此外,pNET 肝转移患者通常会出现衰弱症状。
症状如无法控制的腹泻、潮红、皮疹和心力衰竭。系统性的还很少
已被证明在临床上有用的疗法,以及那些仍然具有广泛变化的反应率的疗法
并且具有较差的副作用。该提案的目标是确定 Notch2 在
NET 的增殖、转移和激素分泌表型,并将 Notch2 评估为
患者结果的预测因子。我们实验室的初步数据表明,Notch2 的过度表达导致
增加 NET 细胞的增殖率,同时减少其激素分泌。我们的数据还
表明与原发性肿瘤相比,Notch2 在转移性 pNET 中表达上调。来自一位的开创性数据
迄今为止关于 pNET 的最大基因组研究也确定了 Notch2 是 pNET 的关键主调节因子
转移,代表疾病进展所需的依赖关系的关键融合
转移的建立。因此,我的假设是,Notch2 具有致癌作用
NET 并驱动肿瘤进展,导致更具侵袭性的表型并预示着更糟的情况
患者预后。为了评估这个假设,我们将进行表型表征(增殖、
Notch2 过表达 pNET 细胞系上的激素产生、迁移)
稳定转染。我们将类似地通过 siRNA 评估具有 Notch2 敲低的 pNET 细胞系,以及
使用 CRISPR-Cas9 生成稳定的敲除 pNET 细胞系。然后我们将在体内进行类似的研究
使用肝转移小鼠模型,其中注射Notch2过表达和Notch2 pNET细胞系
进入无胸腺小鼠。使用该模型,我们将通过 microCT 评估肿瘤生长和转移,此外
16 周期间的激素分泌。然后我们将对肿瘤和小鼠进行终点分析
器官。最后,我们将使用 pNET 组织对 Notch2 的表达进行免疫组织化学分析
来自阿拉巴马大学接受手术切除的人类患者的微阵列
在伯明翰评估Notch2表达、Notch2通路之间的关系
成分和各种患者结果测量。这项研究将产生有关影响的有价值的信息
pNET 中的 Notch2 有助于指导未来的靶向治疗工作并有助于了解
pNET 生物学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brendon Robert Herring其他文献
Brendon Robert Herring的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brendon Robert Herring', 18)}}的其他基金
Characterizing the Role of NOTCH2 in Neuroendocrine Tumors
表征 NOTCH2 在神经内分泌肿瘤中的作用
- 批准号:
10388047 - 财政年份:2022
- 资助金额:
$ 4.13万 - 项目类别:
相似海外基金
Development and Production of Standardized Reference Diets for Zebrafish Research
斑马鱼研究标准化参考饲料的开发和生产
- 批准号:
10823702 - 财政年份:2023
- 资助金额:
$ 4.13万 - 项目类别:
Characterizing the Role of NOTCH2 in Neuroendocrine Tumors
表征 NOTCH2 在神经内分泌肿瘤中的作用
- 批准号:
10388047 - 财政年份:2022
- 资助金额:
$ 4.13万 - 项目类别:
The metabolomic consequences of small size and long life
小尺寸和长寿命的代谢组学后果
- 批准号:
9902281 - 财政年份:2019
- 资助金额:
$ 4.13万 - 项目类别:
The metabolomic consequences of small size and long life
小尺寸和长寿命的代谢组学后果
- 批准号:
10673183 - 财政年份:2019
- 资助金额:
$ 4.13万 - 项目类别:
The metabolomic consequences of small size and long life
小尺寸和长寿命的代谢组学后果
- 批准号:
10661135 - 财政年份:2019
- 资助金额:
$ 4.13万 - 项目类别: